Timothy Schmidt

11PUBLICATIONS
32CO-AUTHORS
Forensic epidemiologyGene and molecular therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 04, 2024
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?

Timothy M Schmidt

|Apr 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman

|Jan 25, 2024
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal

|Dec 15, 2023
Update on the current and future use of CAR-T to treat multiple myeloma.

Zhubin Gahvari, Matthew Brunner, Timothy Schmidt

|Aug 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation.

Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal

|Jun 07, 2023
Making a case for del(1p) as a high-risk abnormality in multiple myeloma.

Timothy M Schmidt

Pageof 2

Frequent Collaborators

4 joint publications

Natalie S Callander

3 joint publications

Luciano J Costa

2 joint publications

Parameswaran Hari

2 joint publications

Jonathan L Kaufman